Endeavor Vision, a Swiss venture firm that invests internationally, has raised $375 million for its second fund committed to commercial-stage healthcare-technology companies.Endeavor, whose investment teams are based in Geneva and Minneapolis, set out to raise $400 million for Endeavor Medtech Growth II LP in late 2019, but didn’t manage to reach its goal, stated Bernard Vogel, co-founder and managing partner with the firm. The pandemic made it challenging to travel and maintain relationships with new investors, he stated, adding that previous investors supplied roughly 55% of the capital in this new fund. Endeavour formed in 2000 and previously was a generalist firm investing in life sciences and technology. Early last decade, the team observed that many medical-technology venture investors were choosing early-stage companies but that less specialized in growth financing for commercial-stage businesses.
Endeavor Vision Closes Latest Medtech Growth Fund at $375 Million
Published by
November 28, 2024
(GMT+2)
WHAT TO READ NEXT
No items found.
STOCK ANALYSIS
MARKET OVERVIEW
SIMILAR NEWS
Ready to get started?
Start trading with the full package, from state of the art platform to free tool and favorable transaction fees.
All investments involve risks, including the possible loss of capital.
www.mexem.com is a website owned and operated by MEXEM Ltd. MEXEM Ltd is a European broker regulated by CySEC, license No. 325/17.
Read our Forms & Disclosures.
Any advertisement or communication concerning the distribution of derivatives falling within the scope of the Regulation of the FSMA of 26 May 2016 governing the distribution of certain derivative financial instruments to retail clients is not addressed to the Belgian public.